Bausch + Lomb (BLCO) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch + Lomb (BLCO) has outperformed Repligen (RGEN) over the past year, gaining 18.3% versus a gain of 14.6%. Repligen is the larger company by market cap ($10.32 billion vs $6.16 billion), about 1.7 times the size. On valuation, Bausch + Lomb trades at a lower forward P/E (15.5x vs 61.4x for Repligen).
Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -7.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLCO | RGEN |
|---|---|---|
| Share price | $17.25 | $162.60 |
| Market cap | $6.16B | $10.32B |
| 1-day change | -0.52% | -2.76% |
| YTD return | +1.52% | +2.05% |
| 1-year return | +18.28% | +14.59% |
| 5-year return | — | -37.35% |
| P/E ratio (TTM) | — | 222.74 |
| Forward P/E | 15.49 | 61.37 |
| EPS (TTM) | $-0.49 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.10B | $738.26M |
| Revenue growth (YoY) | +6.47% | +16.36% |
| Net income (latest FY) | $-360.00M | $48.89M |
| Gross margin | — | 52.32% |
| Operating margin | 2.22% | 7.47% |
| Net margin | -7.06% | 6.62% |
| 52-week high | $18.92 | $198.87 |
| 52-week low | $13.77 | $100.99 |
| Distance from 52-week high | -8.80% | -18.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +12.41% | +19.90% |
| Average volume | 392.13K | 1.17M |
| Shares outstanding | 357.17M | 63.49M |
| Employees | 13,000 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -7.1 cents for Bausch + Lomb.
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs +6.47%).
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Health Care · Ophthalmic Goods · 13,000 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
BLCO vs RGEN FAQ
Which is bigger, Bausch + Lomb or Repligen?
Repligen (RGEN) is larger, with a market capitalization of $10.32B compared with $6.16B for Bausch + Lomb (BLCO).
Which stock has performed better over the past year, BLCO or RGEN?
BLCO returned +18.28% over the past 12 months, compared with +14.59% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Bausch + Lomb and Repligen in the same industry?
Both are in the Health Care sector, but in different industries: Ophthalmic Goods for Bausch + Lomb and Biotechnology: Biological Products (No Diagnostic Substances) for Repligen.